I am talking about doing the work, the funding needs to be in place in a large degree and the researchers will come.
Researchers who have not spent their lives thinking about these problems will come and spend your funding, sure. If you can get sufficient funding in the first place. How will you determine who to spend your money on?
I said already Dr. De Gray. He is not getting the funding he wants. Or are you saying he is not legitimate?
Aubrey has received millions of dollars to demonstrate proof-of-concept. One breakthrough and he will have all the money he could possibly want. He should be more than able to deliver something with the funding he has. The current lysoSENS project is worth several billion per year by itself if it works.
Well this is your theory, what evidence is it actually based upon?
The entire field of regenerative medicine was largely born on a single scientific advance, the derivation of human embryonic stem cells. Californians alone are dumping $6B on this area of research via CIRM, nevermind federal agencies and industry.
Also given the multifaceted nature of aging, and it requiring multiple concurrent therapies, how exactly are you going to manage what you say on a tiny budget?
It is kind of like social media. Many founders starts off with a good idea and a platform, and assumes everyone will come running to populate it. In reality, the companies that are successful can grow a business from a start-up to an industry with incremental, but solid advances. If you want to lose money quickly in investing, dump a ton of it on a single undemonstrated project. If you want to make money, diversify your portfolio, identify emerging talent, and give small seeds to let new talent prove itself.
Take SENS for example. Start with lysoSENS and the known enzymes that degrade A2E. Demonstrate uptake into RPE cells and A2E degradation and spin out a company. That company will not only grow to provide for the unmet medical need for macular degeneration therapies, but also validate the entire concept of medical bioremediation and lysoSENS. That will ultimately net SENS Foundation a substantial return on any intellectual property then own, but also bolster donations because a major component of their technology has been vetted.